Source comparison
Tolerance to Thymosin Alpha-1 Cycling: Comparison Across Peptide Classes
Thymosin Alpha-1 Toll-like receptor modulator (indirect immune signalling) Minimal. 18–36 month studies show sustained efficacy without receptor downregulation 6–8 weeks on, 2–4 weeks off (cost/flexibility driven, not tolerance prevention) Unique among peptide
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1
- Toll-like receptor modulator (indirect immune signalling)
- Minimal. 18–36 month studies show sustained efficacy without receptor downregulation
- 6–8 weeks on, 2–4 weeks off (cost/flexibility driven, not tolerance prevention)
- Unique among peptides. Tolerance to Thymosin Alpha-1 cycling is not a limiting factor; cycling benefits are economic and strategic rather than pharmacological
- Semaglutide (GLP-1 agonist)
- Direct GLP-1 receptor agonist
- Gastric receptor adaptation begins week 8–12; appetite suppression may plateau without dose escalation
- Continuous dosing with 4-week titration; cycling not recommended (rebound hunger upon cessation)
- Tolerance develops predictably. Dose escalation required to maintain effect; discontinuation triggers rebound
- BPC-157
- Growth factor pathway modulator (VEGF, FAK signalling)
- Tissue repair efficacy diminishes after 4–6 weeks continuous use in localised injury protocols
- 4 weeks on, 2 weeks off; or pulsed dosing around training stress windows
- Moderate tolerance. Receptor density normalises during washout; cycling restores responsiveness
- Ipamorelin (GHRP)
- Ghrelin receptor agonist (growth hormone secretagogue)
- Pituitary GH response declines 30–40% after 8 weeks daily dosing
- 5 days on, 2 days off weekly; or 8 weeks on, 4 weeks off
- High tolerance. Receptor desensitisation is pronounced; weekend breaks mitigate but don't eliminate decline
- Melanotan II
- Melanocortin receptor agonist (MC1R, MC4R)
- Skin pigmentation response plateaus after 3–4 weeks; libido enhancement shows faster tachyphylaxis
- Load phase (daily) → maintenance (2–3x weekly); indefinite low-dose maintenance feasible
- Moderate tolerance in pigmentation pathways; sexual side effects diminish faster than tanning response